Implementing a Precision Medicine Thoracic Service Using In-House Reflex Testing in a Large Academic-Community...

Broad genomic testing is necessary to treat patients with stage IV non-small cell lung cancer (NSCLC). This article describes a NSCLC precision medicine service at an academic-community practice and provides model-based estimates of the impact of a similar intervention.

Will implementation of a precision medicine service increase NSCLC next-generation sequencing (NGS) rates, improve testing turnaround times (TATs), and increase rates of actionable genomic alterations (AGAs)?

The Precision Medicine Thoracic (PREDICT) service consists of: (1) system-wide reflex testing of patients with stage IV NSCLC by in-house solid tumor NGS-focused assay and programmed cell death ligand 1 (PD-L1) testing; (2) nurse navigator oversight; (3) the molecular tumor board; and (4) an integrated information portal (OncoTracker) for real-time updates on sample processing, results, and treatment recommendations by the molecular tumor board. A decision analytic model compared 4 strategies: PREDICT vs standard care (send-out sequencing and PD-L1 testing), and sequencing of all patients with stage IV NSCLC vs patients with non-squamous histology findings only.

From January 2016 to December 2018, a total of 626 retrospective patients with stage IV NSCLC were eligible. In the 17 months following the launch of PREDICT, 290 prospective patients were identified. NGS testing rates increased significantly (91.3% vs 60.8%; P < .0001) after PREDICT, whereas TATs from biopsy date were significantly shorter for both NGS (12 vs 18 days; P < .0001) and PD-L1 (7 vs 10 days; P < .0001). AGAs were identified in 29.3% of prospective patients vs 22% of the retrospective cohort (P = .0172). Targeted therapy use increased from 6.8% to 10.6% (P = .048). The decision analytic model predicted superior survival with the PREDICT initiative across all patients, resulting in the highest rates of AGA identification and lowest chemotherapy utilization rates in the first-line setting.

Implementation of a precision medicine service for stage IV NSCLC comprising reflex testing, nurse navigation, a molecular tumor board, and an information portal at a combined academic-community practice led to higher NGS testing rates and shorter TATs. The result was identification of more actionable mutations and higher rates of first-line targeted therapy utilization. Decision analytic modeling suggests the superiority of this initiative across all patients.